Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
December 15, 2016 07:00 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit to Present Phase 2 CoDIFy Trial Data Highlighting Ridinilazole's Preservation of the Microbiome in CDI Patients at ASM Microbe 2016
May 23, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, May 23, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2016
May 10, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, May 10, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Announces Ridinilazole Preserves the Gut Microbiome of Patients With C. difficile Infection in Phase 2 Trial
March 07, 2016 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, March 07, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...